Silexion Therapeutics Corp. announced it has regained compliance with Nasdaq listing requirements, including minimum bid price and shareholders’ equity. The company met the $1.00 per share bid price and $2.5 million shareholders’ equity requirements. Silexion is focused on advancing RNA interference therapies for KRAS-driven cancers and plans to start Phase 2/3 clinical trials for SIL204 in 2026. The company’s recent preclinical data showed up to 97% inhibition rates across multiple cancer types. Silexion is dedicated to developing innovative treatments for solid tumor cancers with mutated KRAS oncogene. For more information, visit their website.

Read more at GlobeNewswire: Silexion Therapeutics Regains Compliance with Nasdaq